

Pfizer Emerging Science & Innovation

/AUTM/media/Events/Documents/Chris-Brown-Systems-
Oncology-AUTM.pdf

Fueling Portfolio Innovation Through External Collaborations

Barbara K. Sosnowski, Ph.D.


This document provides an outline of a presentation and is incomplete without the accompanying oral commentary and discussion. Conclusions and/or potential strategies contained herein are NOT necessarily endorsed by Pfizer management. Any implied strategy would be subject to management, regulatory and legal review and approval before implementation."



Strong Track Record of Approvals

Over the last 6 years >30 Phase 3 starts & >15 key approvals (10 NMEs)

Robust Pipeline Positioned for Sustainable Productivity



Data as of July 28, 2020

~\$8 billion in R&D spend in 2019

Focusing on breakthrough science in areas of high impact



RARE DISEASES



ONCOLOGY



INFLAMMATION & IMMUNOLOGY



INTERNAL MEDICINE



VACCINES

Opportunistic
in Core
Research
Areas



Strategic into
Emerging
Science
Areas

Hematology	Tumor Biology	Rheumatology	Met CV Risk Factors	High Impact Infections
Neuro-musc.	Cancer Immunology	NASH		Maternal
Gene Therapy	Cancer Vaccines	Gastro-intestinal		
		Medical Dermatology		

Repeat Expansion Disorders
DNA Damage Response / Nucleic Acid Sensing
Senescence

Strategic focus on emerging scientific areas

Repeat Expansion Disorders


Interrogating disease modifying modalities for modifying instability and driver assays: Huntington's, ALS, Myotonic Dystrophy, Friedreich's Ataxia



Slow disease progression by preventing somatic expansion of DNA repeats

Senescence


Senescence is a stress response, defined by cell cycle exit that may offer interrogable biology/targets for cancer, fibrosis, and metabolic diseases



Exploring disease modulation through therapy-induced senescence, senomorphics, and senolytics

DNA Damage Response

DNA damage response may represent target substrate for both malignant and repeat expansion diseases.



Developing leadership through partnerships in academia & biotech (Artios, Medivation)


Unlocking Innovation via Flexible Collaboration Vehicles



R&D Collaborations

.....

Research/ strategic alliances, consortia



Targeted BD

.....

Option based deals, licensing, M&A




Innovative Collaboration

.....

***CTI co-discovery
Seed/ Venture Funding***



Emerging Science & Innovation



Pfizer Partnering Ecosystem



FOR MORE INFORMATION:

Barbara Sosnowski, Ph.D.
Vice President, Emerging Science & Innovation
Worldwide Research, Development, & Medical
Pfizer Inc
Cambridge, MA
Mobile: 617-800-7261
Barbara.Sosnowski@Pfizer.com

<http://www.pfizer.com/partnering/areasofinterest/researchanddevelopment>

www.pfizercti.com

pfizer.com/science/therapeutic-areas

pfizer.com/science/drug-product-pipeline





**Breakthroughs
that change
patients' lives**